AppointmentQuris-AI appoints Michel Vounatsos and Yossi Ben Amram in key roles
Appointment
Quris-AI appoints Michel Vounatsos and Yossi Ben Amram in key roles
Vounatsos was appointed Board member and Ben Amram was appointed President, respectively.
Quris-AI has announced that it has appointed former Biogen CEO Michel Vounatsos to its Board of Directors and former Merck & Co. Regional President Yossi Ben Amram as its new President. The pair will work to support the company’s mission to close the clinical prediction gap.
“Adding accomplished pharmaceutical leaders such as Yossi Ben Amram and Michel Vounatsos to our leadership team will be invaluable in our push for a pharma Bio-AI revolution,” said Dr. Isaac Bentwich, CEO and Founder of Quris-AI. “Both bring a deep understanding of industry dynamics, relationships, global growth strategies, and unique perspectives that will be tremendously beneficial as we continue to scale. I look forward to their insights and contribution as they help guide our exceptionally talented and diverse team’s platform development, partnership program, and global growth efforts in the years ahead.”
Before joining Quris-AI, Vounatsos served as CEO and member of the Board of Directors at Biogen. Before that, he spent almost 20 years at Merck & Co. in various senior positions, including President of the MSD China, President of Primary Care & Merck Customer Centricity, and commercial leadership positions throughout Europe. "The BioAI platform is bringing us a new era in drug development and personalized care. I am beyond excited to be a part of the next phase of accelerated innovation, and I look forward to working with the extraordinary team at Quris-AI." He added.
Ben Amram has more than 30 years of experience at several pharmaceutical companies, including Merck & Co., Inc. (known as MSD outside the United States and Canada). While there, he spent over 20 years in key roles, including serving as President of MSD EURAM (Europe, Russia, Africa, and the Middle East) and leading a $4B business covering more than 100 countries. Before that, he held several positions at TEVA Pharmaceuticals in Israel. Currently, Ben Amram serves as a Board Member at clinical-stage biopharma company PolyPid Ltd. "Joining Quris-AI is a privilege, as the company represents the essence of innovation and discovery at the intersection of AI and biology, featuring a stellar team of the best scientists in the field and groundbreaking technology,” he added.
Quris-AI is a Bio-AI clinical prediction platform to help with the safety and efficacy of new drugs. Its fully automated, self-training AI platform accurately predicts clinical safety and efficacy for novel drugs faster and more cost-effectively and also minimizes animal testing. The company is dual-headquartered in Boston and Israel and backed by strategic biotech and big data investors.
